KTX-582

• UNSPSC Description:

  KTX-582 is a potent IRAK4 degrader with DC50 values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model[1][2][3].

• Target Antigen:

  Apoptosis; IRAK; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Immunology/Inflammation;PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ktx-582.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=NC(C(F)(F)F)=CC=C1)NC2=CC3=CN([C@H]4CC[C@H](CN(CCCO[C@H]5C[C@H](NC6=CC=CC(C(N7C(CC8)C(NC8=O)=O)=O)=C6C7=O)C5)C)CC4)N=C3C=C2C(C)(O)C

• Molecular Weight:

  872.93

• References & Citations:

  [1]Matthew Weiss. Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications. Northeastern Section, ACS (NESACS).|[2]Jennifer K. Lue, MD . Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations. American Society of Hematology ASH Annual Meeting|[3]Nello Mainolfi, et al. Irak degraders and uses thereof. WO/2020/113233|[4]Vogelmann A, Robaa D, Sippl W, Jung M. Proteolysis targeting chimeras (PROTACs) for epigenetics research. Curr Opin Chem Biol. 2020 Aug;57:8-16.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2573298-13-0